Catalyst Pharmaceuticals Files 8-K

Ticker: CPRX · Form: 8-K · Filed: 2024-11-06T00:00:00.000Z

Sentiment: neutral

Topics: corporate-filing, 8-K, regulatory

Related Tickers: CPRX

TL;DR

Catalyst Pharma filed an 8-K on Nov 6, 2024. Standard corporate update.

AI Summary

Catalyst Pharmaceuticals, Inc. filed an 8-K on November 6, 2024, reporting other events and financial statements. The filing details the company's incorporation in Delaware and its principal executive offices located at 355 Alhambra Circle, Suite 801, Coral Gables, Florida.

Why It Matters

This 8-K filing provides an update on Catalyst Pharmaceuticals' corporate information and regulatory filings, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new information that would immediately impact the company's risk profile.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of November 6, 2024.

When was Catalyst Pharmaceuticals, Inc. incorporated?

Catalyst Pharmaceuticals, Inc. was incorporated in Delaware.

What is the company's principal executive office address?

The company's principal executive office is located at 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134.

What is the SEC file number for Catalyst Pharmaceuticals, Inc.?

The SEC file number for Catalyst Pharmaceuticals, Inc. is 001-33057.

Does this filing indicate any significant new business developments or financial changes?

This filing appears to be a routine corporate update and does not explicitly detail significant new business developments or financial changes beyond standard reporting requirements.

From the Filing

0001193125-24-252194.txt : 20241106 0001193125-24-252194.hdr.sgml : 20241106 20241106171028 ACCESSION NUMBER: 0001193125-24-252194 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241106 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241106 DATE AS OF CHANGE: 20241106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 241432160 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d882968d8k.htm FORM 8-K Form 8-K NASDAQ false 0001369568 0001369568 2024-11-06 2024-11-06     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 6, 2024     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle Suite 801 Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events On November 6, 2024, the Company issued a press release announcing its results of operations for the three and nine months ended September 30, 2024 and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1.   Item 9.01 Financial Statements and Exhibits.     (d) Exhibits   99.1    Press release

View on Read The Filing